실시간
Endpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off processFierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)
Agilent 2026년 2월 16일

Agilent Technologies (A) Stock Analysis: Unpacking A 34.86% Potential Upside For Investors - DirectorsTalk Interviews

Agilent Technologies (A) Stock Analysis: Unpacking A 34.86% Potential Upside For Investors - DirectorsTalk Interviews

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.